DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zolinza (Vorinostat) - Published Studies

 
 



Zolinza Related Published Studies

Well-designed clinical trials related to Zolinza (Vorinostat)

A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. [2010.07]

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. [2010.01.01]

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. [2010]

A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. [2009.11.15]

Well-designed clinical trials possibly related to Zolinza (Vorinostat)

Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. [2006.01]

Other research related to Zolinza (Vorinostat)

Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. [2011.11.12]

Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. [2011.10.25]

A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. [2011.10.22]

HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. [2011.09]

Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. [2011.07.28]

Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells. [2011.07]

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. [2011.06.07]

Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. [2011.06.01]

Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts. [2011.05.01]

Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. [2011.04.08]

The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sezary syndrome. [2011.04]

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. [2011.03.20]

Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. [2011.03.15]

Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. [2011.02]

Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. [2010.12]

The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. [2010.12]

Synergistic killing effect between vorinostat and target of CD146 in malignant cells. [2010.11.01]

In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter? [2010.11]

Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. [2010.10.10]

Original article. Solubilization of vorinostat by cyclodextrins. [2010.10]

Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer. [2010.10]

Multigene Expression-Based Predictors for Sensitivity to Vorinostat and Velcade in Non-Small Cell Lung Cancer. [2010.09.21]

Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines. [2010.09]

Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway. [2010.08.01]

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. [2010.08.01]

A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. [2010.07.15]

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. [2010.06.03]

Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG). [2010.06]

Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. [2010.05.15]

Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. [2010.05]

Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. [2010.04.01]

Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. [2010.04]

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. [2010.04]

Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. [2010.03]

Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. [2010.01.01]

Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. [2010.01]

A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. [2010]

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. [2009.12.01]

Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. [2009.12]

Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. [2009.11]

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. [2009.10.06]

Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. [2009.10.01]

A phase 2 study of vorinostat in acute myeloid leukemia. [2009.10]

Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. [2009.09.10]

Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. [2009.09]

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. [2009.08.26]

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. [2009.08.15]

Development of vorinostat: current applications and future perspectives for cancer therapy. [2009.08.08]

Vorinostat in solid and hematologic malignancies. [2009.07.27]

Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells. [2009.07.20]

A novel regimen of vorinostat with interferon gamma for refractory Sezary syndrome. [2009.07]

A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. [2009.05.01]

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. [2009.04.20]

Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study. [2009.04]

Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. [2009.03.01]

Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. [2009.01]

A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. [2008.11.01]

FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial. [2008.11]

Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. [2008.10.01]

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. [2008.10]

Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. [2008.09.01]

FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial. [2008.07.30]

Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. [2008.05.15]

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. [2008.05]

Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. [2008.05]

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. [2008.05]

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. [2008.04.19]

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. [2008.03]

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. [2008.02.01]

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. [2008.02]

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. [2007.10]

Vorinostat in cutaneous T-cell lymphoma. [2007.09]

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. [2007.08.01]

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. [2007.07.20]

Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. [2007.07]

Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. [2007.06.15]

Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. [2007.04.15]

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). [2007.01.01]

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. [2007.01]

Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. [2006.12]

Other possibly related research studies

Treatment of cutaneous T-cell lymphoma/mycosis fungoides. [2006.12]

Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) beta-glucuronide and beta-galactoside for application in selective prodrug chemotherapy. [2007.02.15]

In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. [2007.03]

Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. [2006.10.17]

Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. [2006.09.15]

Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. [2006.08.24]

Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. [2006.06]

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. [2006.08.15]

Human endometrial cytodifferentiation by histone deacetylase inhibitors. [2006.02]

Histone hyperacetylation is associated with amelioration of experimental colitis in mice. [2006.04.15]

Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. [2006.04.01]

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. [2006.01.01]

SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. [2006.01]

Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. [2005.11]

Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. [2005.03]

Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. [2005.09.01]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017